{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:26:56Z","timestamp":1768706816344,"version":"3.49.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.neuroscience.2021.07.033","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T06:21:17Z","timestamp":1628144477000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Fenretinide Beneficial Effects on Amyotrophic Lateral Sclerosis-associated SOD1G93A Mutant Protein Toxicity: In Vitro and In Vivo Evidences"],"prefix":"10.1016","volume":"473","author":[{"given":"Isabella","family":"Orienti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Armida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Dobrowolny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Pepponi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Sollazzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Pezzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Casola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Musar\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Popoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Luisa","family":"Potenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2021.07.033_b0005","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/sj.bjc.6600356","article-title":"Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl)retinamide-induced apoptosis","volume":"86","author":"Asumendi","year":"2002","journal-title":"Br J Cancer"},{"issue":"1\u20132","key":"10.1016\/j.neuroscience.2021.07.033_b0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/21678421.2019.1672750","article-title":"Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis","volume":"21","author":"Babu","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"7","key":"10.1016\/j.neuroscience.2021.07.033_b0015","doi-asserted-by":"crossref","first-page":"e0154111","DOI":"10.1371\/journal.pone.0154111","article-title":"Fenretinide (4-HPR) targets caspase-9, ERK 1\/2 and the Wnt3a\/\u03b2-catenin pathway in medulloblastoma cells and medulloblastoma cell spheroids","volume":"11","author":"Bassani","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2006.12.015","article-title":"Lost in translation: treatment trials in the SOD1 mouse and in Human ALS","volume":"26","author":"Benatar","year":"2007","journal-title":"Neurobiol Dis"},{"issue":"7","key":"10.1016\/j.neuroscience.2021.07.033_b0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrn2652","article-title":"Tests to assess motor phenotype in mice: a user's guide","volume":"10","author":"Brooks","year":"2009","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"10.1016\/j.neuroscience.2021.07.033_b0030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.nlm.2004.01.001","article-title":"Short and long-term motor skill learning in an accelerated rotarod training paradigm","volume":"81","author":"Buitrago","year":"2004","journal-title":"Neurobiol Learn Mem"},{"issue":"10","key":"10.1016\/j.neuroscience.2021.07.033_b0035","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1089\/ars.2013.5446","article-title":"The oxidation states of DJ-1 dictate the cell fate in response to oxidative stress triggered by 4-hpr: autophagy or apoptosis?","volume":"21","author":"Cao","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fphys.2020.00063","article-title":"Antioxidant alternatives in the treatment of amyotrophic lateral sclerosis: A comprehensive review","volume":"11","author":"Carrera-Juli\u00e1","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0045","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/172897","article-title":"Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?","volume":"2012","author":"Cazzaniga","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"1","key":"10.1016\/j.neuroscience.2021.07.033_b0050","doi-asserted-by":"crossref","first-page":"11372","DOI":"10.1038\/s41598-018-29386-7","article-title":"Hormetic dose response to L-ascorbic acid as an anti-cancer drug in colorectal cancer cell lines according to SVCT-2 expression","volume":"8","author":"Cho","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0055","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1177\/1535370217706952","article-title":"Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives","volume":"242","author":"Cooper","year":"2017","journal-title":"Exp Boil Med"},{"issue":"4","key":"10.1016\/j.neuroscience.2021.07.033_b0060","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/mus.21260","article-title":"Long-term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis","volume":"39","author":"Crochemore","year":"2009","journal-title":"Muscle Nerve"},{"issue":"419","key":"10.1016\/j.neuroscience.2021.07.033_b0065","doi-asserted-by":"crossref","first-page":"eaal2332","DOI":"10.1126\/scitranslmed.aal2332","article-title":"PPAR\u03b4 activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis","volume":"9","author":"Dickey","year":"2017","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.neuroscience.2021.07.033_b0070","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cmet.2008.09.002","article-title":"Skeletal muscle is a primary target of SOD1G93A-mediated toxicity","volume":"8","author":"Dobrowolny","year":"2008","journal-title":"Cell Metab"},{"issue":"37","key":"10.1016\/j.neuroscience.2021.07.033_b0075","doi-asserted-by":"crossref","first-page":"13860","DOI":"10.1073\/pnas.0605814103","article-title":"Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials","volume":"103","author":"Ferri","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.neuroscience.2021.07.033_b0085","first-page":"2032","article-title":"(2003) Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma","volume":"9","author":"Garaventa","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0090","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1165\/rcmb.2008-0279OC","article-title":"Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide","volume":"41","author":"Guilbault","year":"2009","journal-title":"Am J Respir Cell Mol Boil"},{"issue":"5166","key":"10.1016\/j.neuroscience.2021.07.033_b0095","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1126\/science.8209258","article-title":"Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation","volume":"264","author":"Gurney","year":"1994","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.neuroscience.2021.07.033_b0100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41525-020-00139-8","article-title":"Identity by descent analysis identifies founder events and links SOD1 familial and sporadic ALS cases","volume":"7","author":"Henden","year":"2020","journal-title":"NPJ Genom Med"},{"issue":"9","key":"10.1016\/j.neuroscience.2021.07.033_b0105","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1523\/JNEUROSCI.5253-05.2006","article-title":"Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"26","author":"Kiaei","year":"2006","journal-title":"J Neurosci"},{"issue":"11","key":"10.1016\/j.neuroscience.2021.07.033_b0110","article-title":"The mitochondrial PKC\u03b4\/retinol signal complex exerts real-time control on energy homeostasis","volume":"1865","author":"Kim","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0115","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1038\/sj.onc.1202981","article-title":"4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RAR\u03b3 independent pathway","volume":"18","author":"Kitareewan","year":"1999","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.neuroscience.2021.07.033_b0120","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00415-017-8564-2","article-title":"Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS)","volume":"264","author":"Kuczmarski","year":"2017","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.neuroscience.2021.07.033_b0125","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.3390\/jpm10030101","article-title":"Molecular and cellular mechanisms affected in ALS","volume":"10","author":"Le Galle","year":"2020","journal-title":"J Pers Med"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0130","doi-asserted-by":"crossref","first-page":"109680","DOI":"10.1016\/j.biopha.2019.109680","article-title":"Fenretinide attenuates lipopolysaccharide (LPS)-induced blood-brain barrier (BBB) and depressive-like behavior in mice by targeting Nrf-2 signaling","volume":"125","author":"Li","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"10.1016\/j.neuroscience.2021.07.033_b0135","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1523\/JNEUROSCI.5770-09.2010","article-title":"Fenretinide promotes functional recovery and tissue protection after spinal cord contusion injury in mice","volume":"30","author":"L\u00f3pez-Vales","year":"2010","journal-title":"J Neurosci"},{"issue":"1-2","key":"10.1016\/j.neuroscience.2021.07.033_b0140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/17482960903545334","article-title":"Guidelines for preclinical animal research in ALS\/MND: A consensus meeting","volume":"11","author":"Ludolph","year":"2010","journal-title":"Amyotroph Lateral Scler"},{"issue":"4","key":"10.1016\/j.neuroscience.2021.07.033_b0145","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1535-7163.MCT-16-0749","article-title":"Reactive oxygen species-mediated synergism of fenretinide and romidepsin in preclinical models of T-cell lymphoid malignancies","volume":"16","author":"Makena","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.neuroscience.2021.07.033_b0150","doi-asserted-by":"crossref","first-page":"e27447","DOI":"10.1002\/pbc.27447","article-title":"Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines","volume":"65","author":"Makena","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0155","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/537853","article-title":"Postmitotic expression of SOD1G93A gene affects the identity of myogenic cells and inhibits myoblasts differentiation","volume":"2015","author":"Martini","year":"2015","journal-title":"Mediat Inflamm"},{"issue":"3","key":"10.1016\/j.neuroscience.2021.07.033_b0160","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2337\/db12-0458","article-title":"Fenretinide treatment prevents diet-induced obesity in association with major alterations in retinoid homeostatic gene expression in adipose, liver, and hypothalamus","volume":"62","author":"Mcilroy","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0165","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fbioe.2020.00224","article-title":"Intravenously administered, retinoid activating nanoparticles increase lifespan and reduce neurodegeneration in the SOD1G93A mouse model of ALS","volume":"8","author":"Medina","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0170","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bcp.2014.07.012","article-title":"The mechanisms of Fenretinide-mediated anti-cancer activity and prevention of obesity and type-2 diabetes","volume":"91","author":"Mody","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0175","doi-asserted-by":"crossref","unstructured":"Moore MM, Stockler MR, Lim R, Mok T.S, Millward M, Boyer M (2010) A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. Cancer Chemother Pharmacol 66, 845\u2013850.","DOI":"10.1007\/s00280-009-1228-x"},{"issue":"1\u20132","key":"10.1016\/j.neuroscience.2021.07.033_b0180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/21678421.2019.1632346","article-title":"Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial","volume":"21","author":"Mora","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0185","doi-asserted-by":"crossref","unstructured":"Musar\u00f2 A (2010) State of the art and the dark side of amyotrophic lateral sclerosis. World J Biol Chem. 26; 1(5):62-8.","DOI":"10.4331\/wjbc.v1.i5.62"},{"issue":"5","key":"10.1016\/j.neuroscience.2021.07.033_b0190","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/sj.leu.2402485","article-title":"N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes","volume":"16","author":"O\u2019Donnell","year":"2002","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.neuroscience.2021.07.033_b0195","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1471-4159.2011.07298.x","article-title":"Muscle cells and motoneurons differentially remove mutant SOD1 causing familial amyotrophic lateral sclerosis","volume":"118","author":"Onesto","year":"2011","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0200","first-page":"292","article-title":"Nanoencapsulation of fenretinide in glucosamine butyrate gelatin matrices as a mean to improve its oral bioavailability","volume":"6","author":"Orienti","year":"2015","journal-title":"J Nanomed Nanotechnol"},{"issue":"1","key":"10.1016\/j.neuroscience.2021.07.033_b0205","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s13046-019-1383-9","article-title":"A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells","volume":"38","author":"Orienti","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.neuroscience.2021.07.033_b0210","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41419-019-1775-y","article-title":"A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors","volume":"10","author":"Orienti","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0215","doi-asserted-by":"crossref","unstructured":"Orienti I, Gentilomi GA, Farruggia G (2020) Pulmonary delivery of fenretinide: a possible adjuvant treatment in COVID-19. Int J Mol Sci. 27;21(11):3812.","DOI":"10.3390\/ijms21113812"},{"issue":"5","key":"10.1016\/j.neuroscience.2021.07.033_b0220","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neurol.2019.09.008","article-title":"The effects of diet and sex in amyotrophic lateral sclerosis","volume":"176","author":"Pape","year":"2020","journal-title":"Rev Neurol"},{"issue":"4","key":"10.1016\/j.neuroscience.2021.07.033_b0225","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s13311-016-0462-2","article-title":"Fingolimod: a disease-modifier drug in a mouse model of amyotrophic lateral sclerosis","volume":"13","author":"Potenza","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"21","key":"10.1016\/j.neuroscience.2021.07.033_b0230","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2004.09.096","article-title":"Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study","volume":"22","author":"Puduvalli","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.neuroscience.2021.07.033_b0235","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4049\/jimmunol.154.1.450","article-title":"Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course","volume":"154","author":"Racke","year":"1995","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.neuroscience.2021.07.033_b0240","doi-asserted-by":"crossref","first-page":"e0210752","DOI":"10.1371\/journal.pone.0210752","article-title":"Chemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse model of ALS","volume":"14","author":"Rando","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0245","doi-asserted-by":"crossref","unstructured":"Reynolds CP, Frgala T, Tsao-Wei DD, Groshen S, Morgan R, McNamara M, Scudder S, Zwiebel JA et al. (2007) High plasma levels of fenretinide (4-HPR) were associated with improved outcome in a phase II study of recurrent ovarian cancer: A study by the California Cancer Consortium. J Clin Oncol 25: 5555.","DOI":"10.1200\/jco.2007.25.18_suppl.5555"},{"issue":"3","key":"10.1016\/j.neuroscience.2021.07.033_b0250","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jcf.2007.09.001","article-title":"Fenretinide prevents the development of osteoporosis in Cftr-KO mice","volume":"7","author":"Saeed","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.neuroscience.2021.07.033_b0255","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/jcp.24527","article-title":"Fenretinide induces ubiquitin-dependent proteasomal degradation of stearoyl-CoA desaturase in human retinal pigment epithelial cells","volume":"229","author":"Samuel","year":"2014","journal-title":"J Cell Physiol"},{"issue":"8","key":"10.1016\/j.neuroscience.2021.07.033_b0260","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/oby.21164","article-title":"Fenretinide prevents obesity in aged female mice in association with increased retinoid and estrogen signaling","volume":"23","author":"Shearer","year":"2015","journal-title":"Obesity (Silver Spring)"},{"issue":"10","key":"10.1016\/j.neuroscience.2021.07.033_b0265","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3390\/biomedicines8100434","article-title":"Low dose astaxanthin treatments trigger the hormesis of human astroglioma cells by up-regulating the cyclin-dependent kinase and down-regulated the tumor suppressor protein P53","volume":"8","author":"Shin","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0270","series-title":"Molecular and neurological effects of fenretinide on amyotrophic lateral sclerosis","author":"Skinner","year":"2008"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0275","first-page":"35","article-title":"Modelling amyotrophic lateral sclerosis in mice","volume":"25\u201326","author":"Stephenson","year":"2017","journal-title":"Drug Discovery Today: Disease Models"},{"issue":"2","key":"10.1016\/j.neuroscience.2021.07.033_b0280","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1248\/bpb.23.222","article-title":"Antioxidant properties of N-(4-hydroxyphenyl)retinamide (fenretinide)","volume":"23","author":"Takahashi","year":"2000","journal-title":"Biol Pharm Bull"},{"issue":"10","key":"10.1016\/j.neuroscience.2021.07.033_b0285","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.3390\/ijms21103647","article-title":"Genetics and sex in the pathogenesis of amyotrophic lateral sclerosis (ALS): is there a link?","volume":"21","author":"Trojsi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neuroscience.2021.07.033_b0290","doi-asserted-by":"crossref","unstructured":"Vegeto E, Villa A, Della Torre S, Crippa V, Rusmini P, Cristofani R, Galbiati M, Maggi A et al. (2020) The role of sex and sex hormones in neurodegenerative diseases. Endocr Rev. 1;41(2):273\u2013319.","DOI":"10.1210\/endrev\/bnz005"},{"issue":"7","key":"10.1016\/j.neuroscience.2021.07.033_b0295","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/annonc\/mdl047","article-title":"Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer","volume":"17","author":"Veronesi","year":"2006","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.neuroscience.2021.07.033_b0300","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1158\/1078-0432.CCR-11-0995","article-title":"Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR\/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group","volume":"17","author":"Villablanca","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.neuroscience.2021.07.033_b0305","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1073\/pnas.1302352110","article-title":"Preferential eradication of acute myelogenous leukemia stem cells by fenretinide","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452221003870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452221003870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T16:07:56Z","timestamp":1759680476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452221003870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":60,"alternative-id":["S0306452221003870"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2021.07.033","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fenretinide Beneficial Effects on Amyotrophic Lateral Sclerosis-associated SOD1G93A Mutant Protein Toxicity: In Vitro and In Vivo Evidences","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2021.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 IBRO. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}